Hackensack 385 Prospect Avenue Suite 101 Hackensack, NJ, 07601

ORDERING PROVIDER

Provider \_

Signature X \_\_\_\_\_\_ Date \_\_\_\_

\_\_\_\_\_ Phone \_\_\_\_\_ Fax \_

Princeton / Somerset 49 Veronica Avenue Suite 202 Somerset, NJ 08873

Long Branch 422 Morris Avenue Suite 7 Long branch, NJ 07740

*Marlton* 127 Church Road Suite 600 Marlton, NJ 08053



NPI\_\_\_



| $\mathbf{VIMIZIM}^{\circ}$ (elosu  | lfase alfa)   | ORDER FORM   | Date:                                    |
|--|---|--|--|
|  | <u>PA</u> TI  | ENT INFORMATION  |  |
| Name:  | Phone:  |  | DOB: SEX: M $\square$ F $\square$        |
| □NKDA Allergies:   |   |  | Weight lbs/kg:                           |
|  |   | CIAN INFORMATIO  | N  |
| ,  |   | ractice Name:  | 000                                      |
|  |   | fice Contact Name: Office Contact #:                   |  |
|  |   | il (for updates):                                      |  |
| □New Referral □Referral Renev  |   | FERRAL STATUS  rder Change □ Benefits Ver              | ification Only Discontinuation Order     |
| VIMIZIM®:  UIMIZIM is indicated for patients with the control of t | vith Mucopolysacchari                                   | dosis type IVA (MPS IVA; Morq                          | juio A syndrome). E76.210                |
| DOSAGE AND ADMINISTRAT Recommended Dose Pre-treatment with antihistamines with or recommended 30 to 60 minutes prior to  PRE-MEDICATION  Tylenol PO 650mg  | r without antipyretics is the start of the infusion.  r | <del>-</del>   | _ X weeks                                |
| Life-threatening anaphylactic reactions have occurred in some patients during VIMIZIM (elosulfase alfa) infusions.  Anaphylaxis, presenting as cough, erythema, throat tightness, urticaria, flushing, cyanosis, hypotension, rash, dyspnea, chest discomfort, and gastrointestinal symptoms (e.g., nausea, abdominal pain, retching, and  |   | REQUIRED DOCUM   | ENTATION CHECKLIST:                      |
|  |   | Patient Demograp                                       | hics                                     |
| vomiting) in conjunction with urticaria, have been reported to occur<br>during VIMIZIM (elosulfase alfa) infusions, regardless of duration of the  |   | Insurance Card/Inf                                     | formation                                |
| course of treatment.   |   | Recent Progres notes addressing <b>VIMIZIM</b> in note |  |
| Closely observe patients during and after VIMIZIM (elosulfase alfa)  |   | Pagent labe to incl                                    | lude CPC CAAD and places cond any other  |
| administration and be prepared to manage anaphylaxis. Inform patients of the signs and symptoms of anaphylaxis and have them seek immediate  |   |  | lude CBC, CMP, and please send any other |
| medical care should symptoms occur. Patients with acute respiratory  |   |  |  |
| illness may be at risk of serious acute exace compromise due to hypersensitivity reaction monitoring.  |   | Other  |  |